Drug intelligence / Profile preview

BiOLinkMatrix HA

Development stage: Unknown
Lead developer: HALLURA
Administration: Subcutaneous, Intradermal

Overview

BiOLinkMatrix HA is a proprietary **hyaluronic acid dermal filler platform** developed by Hallura for aesthetic soft-tissue augmentation. It uses crosslinked hyaluronic acid produced with a **bio-orthogonal chemistry approach inspired by click chemistry**, designed to avoid BDDE-based crosslinking used in many conventional HA fillers. According to the provided context, this approach is intended to reduce impurities, enable lower HA concentrations, and preserve more natural physical properties of the HA biopolymer while maintaining filler durability. The product has been studied for **lip enhancement, nasolabial folds correction, and cheek enhancement**, with reported positive topline results from a European multi-site clinical study and durability out to 9 months after treatment.

Other names: BiOLinkMatrix HA

Beyond the preview

Go deeper on BiOLinkMatrix HA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BiOLinkMatrix HA.

Explore the full profile